- Home
- MFC vs ARGX Comparison
MFC vs ARGX Comparison
Compare MFC & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFC
- ARGX
- Stock Information
- Founded
- MFC 1887
- ARGX 2008
- Country
- MFC Canada
- ARGX Netherlands
- Employees
- MFC N/A
- ARGX N/A
- Industry
- MFC Life Insurance
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFC Finance
- ARGX Health Care
- Exchange
- MFC Nasdaq
- ARGX Nasdaq
- Market Cap
- MFC 49.3B
- ARGX 40.4B
- IPO Year
- MFC 1999
- ARGX 2017
- Fundamental
- Price
- MFC $28.61
- ARGX $596.20
- Analyst Decision
- MFC Strong Buy
- ARGX Strong Buy
- Analyst Count
- MFC 2
- ARGX 20
- Target Price
- MFC $45.50
- ARGX $699.56
- AVG Volume (30 Days)
- MFC 2.7M
- ARGX 465.0K
- Earning Date
- MFC 05-07-2025
- ARGX 05-08-2025
- Dividend Yield
- MFC 4.21%
- ARGX N/A
- EPS Growth
- MFC 8.81
- ARGX N/A
- EPS
- MFC 1.97
- ARGX 12.78
- Revenue
- MFC $20,844,569,236.00
- ARGX $2,248,205,000.00
- Revenue This Year
- MFC $41.78
- ARGX $57.86
- Revenue Next Year
- MFC $7.54
- ARGX $31.90
- P/E Ratio
- MFC $13.94
- ARGX $43.64
- Revenue Growth
- MFC 10.08
- ARGX 77.22
- 52 Week Low
- MFC $22.81
- ARGX $352.77
- 52 Week High
- MFC $33.07
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- MFC 45.85
- ARGX 51.80
- Support Level
- MFC $28.28
- ARGX $583.00
- Resistance Level
- MFC $29.25
- ARGX $610.06
- Average True Range (ATR)
- MFC 1.33
- ARGX 24.42
- MACD
- MFC -0.10
- ARGX 4.74
- Stochastic Oscillator
- MFC 41.64
- ARGX 84.66
About MFC Manulife Financial Corporation
Manulife Financial provides life insurance, annuities, and asset management products to individuals and group customers in Canada, the United States, and Asia. Its investment management business contributes approximately 20% of its earnings and has around CAD 1.05 trillion in assets under management and administration as of the end of 2023. The US business, which primarily operates under the John Hancock brand, contributes about 27% of earnings and is mainly focused on providing insurance products for estate, business, and income protection. The Asia segment provides insurance products and insurance-based wealth accumulation products in over 11 countries and contributes around 30% of earnings. The Canadian business segment contributes approximately 23% of earnings.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.